Source comparison
Where Sermorelin Trials Succeed vs Fail
Sermorelin help sarcopenia research most reliably in three specific contexts: (1) aging models with confirmed GH deficiency (serum GH <0.5 ng/mL at baseline), (2) protocols combining sermorelin with resistance training or mechanical load, and (3) studies suppl
This comparison does not assign a generated winner or score.
- Sermorelin help sarcopenia research most reliably in three specific contexts: (1) aging models with confirmed GH deficiency (serum GH <0.5 ng/mL at baseline), (2) protocols combining sermorelin with resistance training or mechanical load, and (3) studies supplementing with branch-chain amino acids to meet elevated mTOR activation thresholds.
- A 2025 meta-analysis in Age and Ageing reviewed 14 preclinical trials using GHRH analogs in sarcopenia models. Success. Defined as ≥8% lean mass increase or ≥15% grip strength improvement. Occurred in 9 of 14 studies. The five failures shared common features: baseline GH levels were normal or mildly reduced (not deficient), no exercise intervention was included, and dietary protein remained at maintenance levels (1.0–1.2g/kg). The successful trials all corrected at least two of those variables.
- One standout example: a 2024 trial at Seoul National University used sermorelin (0.4mg daily) in aged rats with diet-induced sarcopenia. The sermorelin-only group showed 5.3% lean mass gains. The sermorelin + progressive resistance training group gained 19.7%. The training-only group (no peptide) gained 8.1%. The synergy was undeniable. And mechanistically predictable. Exercise upregulates IGF-1 receptor expression and mTOR sensitivity, creating the signaling environment GH needs to drive muscle synthesis.
- Failures most often occur when researchers expect sermorelin to reverse sarcopenia without addressing the parallel deficits: motor unit dropout, satellite cell senescence, chronic low-grade inflammation, and mitochondrial dysfunction. GH doesn't repair these. It amplifies whatever anabolic capacity remains. If that capacity is near zero (as in very advanced sarcopenia), even supraphysiological GH won't restore muscle mass.
- Whey isolate
- 3.2g
- High. If consumed within 60 min post-resistance training
- Post-workout anabolic window
- Strong. Elevates both IGF-1 signaling and substrate availability
- Ideal pairing for GH secretagogue protocols targeting muscle preservation
- Casein
- 2.4g
- Moderate. Slow release limits peak leucine threshold
- Overnight muscle protein synthesis
- Moderate. Sustained release doesn't align with GH pulse timing
- Better for non-training days when GH isn't acutely elevated
- Collagen peptides
- 0.9g
- Low. Insufficient leucine to activate mTOR in sarcopenic tissue
- Connective tissue support, not muscle anabolism
- Minimal. Doesn't address the leucine bottleneck
- Not recommended as primary protein in sermorelin sarcopenia trials
- Soy protein isolate
- 2.5g
- Moderate. Effective if total daily leucine >3g/kg
- Plant-based protocols
- Moderate. Requires higher total intake to match whey efficacy
- Viable alternative with leucine co-supplementation